Prostaglandin F2alpha Antikörper (HRP)

Produktnummer ABIN679697

Produktdetails anti-Prostaglandin F2alpha Antikörper (HRP)

Target: Prostaglandin F2alpha

Reaktivität: Hormone

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Prostaglandin F2alpha Antikörper ist konjugiert mit HRP

Applikation: ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Kreuzreaktivität: Ratte

Kreuzreaktivität (Details): PGF2 Alpha

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated to PGF2 Alpha

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IHC-P 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: Gentamicin sulfate

Vorsichtsmaßnahmen: This product contains Gentamicin sulfate: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Do NOT add Sodium Azide! Use of Sodium Azide will inhibit enzyme activity of horseradish peroxidase.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu Prostaglandin F2alpha

Target: Prostaglandin F2alpha

Andere Bezeichnung: Pgf2 alpha (Prostaglandin F2alpha Produkte)

Substanzklasse: Hormone

Hintergrund:

Synonyms: Prostaglandin F2 Alpha, PGF2 Alpha, 5Z,9,11,13E,15S-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt, PGF2−,Tris.

Background: Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. A positive feedback loop between endometrial PG F2 and luteal oxytocin is responsible for completion of luteolysis.Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. Also stimulates contraction of smooth muscle, such as in bronchi, with possible involvement in asthma. This effect is at least partially mediated through tachykinin release.